Artios Pharma is a leading independent DNA Damage Response (DDR) company dedicated to discovering and developing innovative precision medicines for the treatment of cancer. With a strong pipeline of novel cancer therapies, Artios aims to provide first and best-in-class treatments to benefit patients. The company's leadership team, including CEO Niall Martin, brings over 30 years of extensive experience in the cancer therapeutics field.

Niall has successfully raised significant funds for Artios, including a ground-breaking $153M Series C financing in July 2021. He has a remarkable track record, having contributed to the discovery and development of Lynparza™ (olaparib), the first PARP inhibitor to reach the market. Artios also boasts a team of scientific advisors and a board with expertise in DDR research, further strengthening their capabilities in developing targeted anti-cancer agents.

The company's dedication to advancing the DDR field has positioned them as a leader in this area. With a focus on precision medicine, Artios is committed to improving outcomes for cancer patients through their innovative drug discovery platform and robust pipeline of therapies, including their ATR Inhibitor ART0380 and Pol Theta Inhibitor Program. Artios is backed by reputable investors including Merck KGaA and Novartis, which further validates the potential of their pipeline and research.

Join Artios in their mission to transform cancer treatment through cutting-edge science and patient-centric approaches